Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — Investor Presentation (November 2013)
14 slides from Anavex Life Sciences's investor presentation, Nov 12, 2013
Slide 1: Anavex Life Sciences Corp. Corporate Presentation 2013
SY anevex LIFE SCIENCES Corp. OTCQB: AVXL Corporate Presentation 2013
Slide 2: biel
Pe biel
Slide 3: Lower clinical trial risk with Aricept (donepezil) combination
• Lower clinical trial risk since one compound Aricept® (donepezil) is already on market, selling $4 billion annually • Aricept® (donepezil) is now generic • ANAVEX 2-73: Able to reverse memory and learning deficits and protect nerve cells from neurodegeneration and cell death • Patent application f
Slide 4: Preclinical Phase pipeline
PRECLINICAL PHASE 1 PHASE 2 ANAVEX PLUS. ALZHEIMER'S } ANAVEX 2-73 ay 2HEIMER'S EPILEPSY ANAVEX 19-144 ‘ANAVEX 1-41 ALZHEIMER'S DEPRESSION ‘STROKE ‘ANAVEX 1079 CANCER (MELANOMA) INFLAMMATORY & NEUROPATHIC PAIN ANAVEX 1005 CANCER (PANCREAS) ACUTE & NEUROPATHIC PAIN ANAVEX 1007 CANCER (PROSTATE) ACUTE
Slide 5: Cells within brain transport electrical messages
• Cells within brain ( neurons ) transport electrical messages to other parts of the body using chemical transmitters ( neurotransmitters ) • In Alzheimer’s disease , areas of brain tissue are damaged and some messages do not transmit, causing the symptoms • Eventually, Alzheimer's disease leads to
Slide 6: Stages of Alzheimer's
Stages of Alzheimer’s Loss of speech; locomotion, consciousness; death Full-time care needed; institutionalized Can no longer take care for self; incontinent, depressed Can no longer manage personal affairs; agitated, care needed Family and friends notice problems Increased burden
Slide 7: Disease Center, IMS
Sources: Alzheimer’s Association, ICAD, UC Davis Alzheimer’s Disease Center, IMS
Slide 8: More effective treatments will create a multibillion dollar market
• More effective treatments will create a multibillion dollar product market opportunity Source: Alzheimer’s Association, ICAD, UC Davis Alzheimer’s Disease Center, IMS, Orange Book
Slide 9: Free-floating Abeta oligomers damage brain cells
• Free-floating particles of Abeta (oligomers) damage brain cells in conjunction with hyper-phosporylation of Tau • Healthy brain cells actually have ability to clear Abeta proteins very quickly when not distressed • Neuro-protective strategy may help the brain to preserve this ability in distressed
Slide 10: Sig-1R and ANAVEX 2-73 mode of action
• Endogenous Sig-1R expressed to attenuate stress level and dendrites regeneration • Chronic cell stress possibly causing Alzheimer’s disease • Pharmacological potential of mixed musicarinic / Sig-1R agonist (ANAVEX 2-73): Three way mode of action: Ca 2+ modulation and indirectly targeting both Abet
Slide 11: Neuroprotective effects of ANAVEX 2-73 and donepezil
• Donepezil (0.5 mg/kg) or PRE-084 (1 mg/kg) significantly reduces Ab25–35 peptide-induced oxidative stress • ANAVEX 2-73 (0.3 and 1 mg/kg) appeared to be effective neuro-protective doses at morphological, biochemical and behavioral level of analysis British Journal of Pharmacology (2006) 149 998–10
Slide 12: ANAVEX PLUS: potential novel combination drug for Alzheimer's
• “ANAVEX PLUS”: Potential novel combination drug for Alzheimer’s • Lower clinical trial risk since one compound (donepezil) already on the market, selling $4 billion annually
Slide 13: Multiple ascending dose study in mild-moderate AD
Multiple ascending dose study (MAD) / Mild-(moderate) AD atients (40-100) . ANAVEX 2-73/DPZ Dose A Multi ple ——+ ANAVEX 2-73/DPZ Dose B sites “+ ponepezil (DPZ) Start: Q4 2013 or later Duration: 3 months Endpoint: Determine a tolerated repeat dose and extend safety exposure for ANAVEX 2-73/DPZ; dete
Slide 14: Anavex is working on a potential solution
… Anavex is working on a potential solution .
Anavex Life Sciences — Investor Presentation (November 2013) on 6ix